(Total Views: 685)
Posted On: 11/26/2022 9:39:59 PM
Post# of 153940
MG, don’t mean to butt in, in any way, since you addressed Sean with this question….
“ do you feel that by getting rid of Nitya Ray, that the formula to Leronlimab could be compromised in any way? That the formula for assembly and / or manufacturing could be decoded in any way?”
IMHO, the secret to creating murine monoclonal antibodies isn’t news. It won’t be too hard to copy. Many probably are prepped to do so.
The issue you should investigate is patent expirations. It sounds to me like our earliest expirations are for early formulation, and our later patents will be in full effect for longer. The shorts will say we’re all screwed because “the patent” is expiring. But we have patents very specifically designed for different applications that will have full life expectancy. IMHO.
Please correct me if I’ve missed anything or have misstated anything.
Chazzle
“ do you feel that by getting rid of Nitya Ray, that the formula to Leronlimab could be compromised in any way? That the formula for assembly and / or manufacturing could be decoded in any way?”
IMHO, the secret to creating murine monoclonal antibodies isn’t news. It won’t be too hard to copy. Many probably are prepped to do so.
The issue you should investigate is patent expirations. It sounds to me like our earliest expirations are for early formulation, and our later patents will be in full effect for longer. The shorts will say we’re all screwed because “the patent” is expiring. But we have patents very specifically designed for different applications that will have full life expectancy. IMHO.
Please correct me if I’ve missed anything or have misstated anything.
Chazzle
(4)
(0)
